PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial NEW YORK, NY--(Marketwired - December 12, 2016) - All of the pieces are starting to fall into place for PharmaCyte Biotech (OTCQB: PMCB) and its upcoming human clinical trial in advanced pancreatic...

PharmaCyte Biotech Moves Closer to Revealing Plan to Address Unmet Medical Need in Phase 2b Clinical Trial BONITA, CA--(Marketwired - September 30, 2015) - Cancer is the world's second most common cause of death, not too far behind heart disease. And, although no form of cancer is "good," pancreatic cancer...

PharmaCyte Biotech's Improved Technology Attracting World Class Oncologists NEW YORK, NY--(Marketwired - July 30, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is a small international biotechnology firm, but you wouldn't know it by the company it keeps. How does PharmaCyte keep...

PharmaCyte Biotech's Cancer Treatment Shows "Complete Tumor Remission" in Published Preclinical Study NEW YORK, NY--(Marketwired - June 03, 2015) - PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, was the star of the show in a recently released corporate...